Financial Snapshot

Revenue
$6.654M
TTM
Gross Margin
46.42%
TTM
Net Earnings
-$52.49M
TTM
Current Assets
$7.614M
Q2 2024
Current Liabilities
$5.395M
Q2 2024
Current Ratio
141.13%
Q2 2024
Total Assets
$9.965M
Q2 2024
Total Liabilities
$5.395M
Q2 2024
Book Value
$4.570M
Q2 2024
Cash
P/E
-0.04533
Nov 29, 2024 EST
Free Cash Flow
-$8.601M
TTM

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2023 2022 2021
Revenue $2.160M $2.620M $41.43K
YoY Change -17.55% 6223.15%

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2023 2022 2021
Revenue $2.160M $2.620M $41.43K
Cost Of Revenue $1.909M $566.3K $43.02K
Gross Profit $111.4K $3.270M -$1.590K
Gross Profit Margin 5.16% 124.81% -3.84%

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2023 2022 2021
Selling, General & Admin $5.879M $19.85M $5.810M
YoY Change -70.38% 241.61%
% of Gross Profit 5275.14% 607.04%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $4.284M $3.763M $309.0K
YoY Change 13.83% 1117.82%
% of Gross Profit 3843.67% 115.1%
Operating Expenses $10.16M $23.45M $6.119M
YoY Change -56.65% 283.17%
Operating Profit -$10.05M -$20.18M -$6.121M
YoY Change -50.18% 229.65%

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2023 2022 2021
Interest Expense $14.64K -$887.2K -$1.298M
YoY Change -101.65% -31.63%
% of Operating Profit
Other Income/Expense, Net $2.705M $12.76M $50.00
YoY Change -78.8% 25521940.0% -100.01%

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2023 2022 2021
Pretax Income -$32.28M -$8.235M -$8.131M
YoY Change 291.9% 1.28%
Income Tax
% Of Pretax Income
Net Earnings -$32.28M -$11.66M -$8.131M
YoY Change 176.86% 43.37% 253.44%
Net Earnings / Revenue -1494.18% -445.0% -19626.36%
Basic Earnings Per Share
Diluted Earnings Per Share -$286.60 -$0.38 -$501.2K

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2023 2022 2021
Cash & Short-Term Investments $82.82K $492.5K $3.495M
YoY Change -83.18% -85.91%
Cash & Equivalents
Short-Term Investments $0.00 $263.7K
Other Short-Term Assets $151.6K $1.036M $242.5K
YoY Change -85.36% 327.03%
Inventory $1.287M $1.057M $0.00
Prepaid Expenses
Receivables $284.5K $1.236M $242.4K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $1.806M $3.821M $3.980M
YoY Change -52.74% -4.0%
Property, Plant & Equipment $2.641M $12.48M $3.807M
YoY Change -78.84% 227.94%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $7.034M $35.18M $4.066M
YoY Change -80.0% 765.18%
Total Assets $8.840M $39.00M $8.046M
YoY Change
Accounts Payable $6.015M $7.140M $680.3K
YoY Change -15.76% 949.46%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $1.366M $936.8K $7.148M
YoY Change 45.85% -86.9%
Long-Term Debt Due $135.3K $214.1K $439.7K
YoY Change -36.77% -51.32%
Total Short-Term Liabilities $10.17M $9.348M $8.268M
YoY Change 8.81% 13.05%
Long-Term Debt $2.497M $2.749M $1.979M
YoY Change -9.16% 38.9%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $2.497M $2.749M $1.979M
YoY Change -9.16% 38.9%
Total Liabilities $12.67M $12.10M $10.25M
YoY Change 4.73% 18.05%

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2023 2022 2021
Basic Shares Outstanding
Diluted Shares Outstanding
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Free Cash Flow Margin

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $2.3798 Million

About AKANDA CORP.

Akanda Corp is a GB-based company operating in Pharmaceuticals industry. Akanda Corp. is an international medical cannabis and wellness platform company. The Company’s portfolio includes Canmart Ltd. (CanMart), a United Kingdom-based fully licensed pharmaceutical importer and distributor which supplies pharmacies and clinics within the United Kingdom. Canmart is a licensed importer and distributor of CBD Extraction for Medicinal Purposes (CBPMs) in the United Kingdom. CanMart holds a controlled drug license issued by the Home Office to possess and supply CBPMs in the United Kingdom. The firm's seed-to-patient supply chain also includes partnerships Cellen Life Sciences' Leva Clinic, a fully digital pain clinic in the United Kingdom. The firm also develops a Canadian farming property in British Columbia, including farming land and related operations and licenses. The firm also focuses on developing tetrahydrocannabinol (THC) and cannabinoid (CBD) facilities at this site.

Industry: Medicinal Chemicals & Botanical Products Peers: